Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change
This article was originally published in The Tan Sheet
Executive Summary
GSK also recently posted to the alli brand website statements on why language was added to the Drug Facts panel for the orlistat 60 mg product. FDA contacted Glaxo in November 2013 requesting a supplement NDA for the label change, FDA’s Division of Nonprescription Clinical Evaluation said.
You may also be interested in...
In Brief: Shasun Buys Nuprin, DSM And GSK Earnings, Ad Claims Referred To FTC
Shasun acquires ibuprofen products; DSM predicts nutrition sales will increase; GSK sales fall on supply chain trouble; Nature’s Medicine Associates’ ad referred to FTC; Heinrich co-sponsors designer steroid bill; and AHPA eases botanical identification burden.
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.
Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives
GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.